drugset / Trial / NCT04894435
Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity
Phase 2
Active not recruiting
669 enrolled
Canadian Immunization Research Network
BC Children's Hospital Research Institute · collabCHU de Quebec-Universite Laval · collabCanadian Center for Vaccinology · collabChildren's Hospital Research Institute of Manitoba · collabInterior Health · collabMassachusetts General Hospital · collabMcGill University Health Centre/Research Institute of the McGill University Health Centre · collabOntario Agency for Health Protection and Promotion · collabOttawa Hospital Research Institute · collabUniversity of Toronto · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
The main goals of this study are to assess the immune response and safety of two different vaccines for first, second, third and fourth doses as well as for differing intervals between the first and second dose of two-dose vaccines.
Timeline
- Start
- 2021-05-20
- Primary completion
- 2024-11-15
- Completion
- 2025-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | BNT162b2 | Messenger RNA (mRNA) | 0.3 ml | Intramuscular |
| Comparator | ChAdOx-1-S[recombinant] | Vaccine | 0.5 ml | Intramuscular |
| Subject | Covifenz | Vaccine | 0.5 ml | Intramuscular |
| Comparator | Elasomeran | Messenger RNA (mRNA) | 0.2 mg/ml | Intramuscular |
| Comparator | Elasomeran | Messenger RNA (mRNA) | 0.25 ml | Intramuscular |